antiGPIIBIIIa en es it fr

antiGPIIBIIIa Brand names, antiGPIIBIIIa Analogs

antiGPIIBIIIa Brand Names Mixture

  • No information avaliable

antiGPIIBIIIa Chemical_Formula


antiGPIIBIIIa RX_link

antiGPIIBIIIa fda sheet


antiGPIIBIIIa msds (material safety sheet)

antiGPIIBIIIa Synthesis Reference

(sequence listed in Kohmura C, Gold HK, Yasuda T, Holt R, Nedelman MA, Guerrero JL, Weisman HF, Collen D. A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons.Arterioscler Thromb. 1993 Dec;13(12):1837-42.) patent EP418316

antiGPIIBIIIa Molecular Weight


antiGPIIBIIIa Melting Point

61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).

antiGPIIBIIIa H2O Solubility

No information avaliable

antiGPIIBIIIa State




antiGPIIBIIIa Dosage Forms

Solution (IV Infusion)

antiGPIIBIIIa Indication

For treatment of myocardial infarction, adjunct to percutaneous coronory intervention, unstable angina

antiGPIIBIIIa Pharmacology

Used for the treatment of myocardial infarction and the prevention of platelet aggregation. Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets.

antiGPIIBIIIa Absorption

No information avaliable

antiGPIIBIIIa side effects and Toxicity

No information avaliable

antiGPIIBIIIa Patient Information

No information avaliable

antiGPIIBIIIa Organisms Affected

Humans and other mammals